XBiotech Inc. - Common Shares, no par value (XBIT) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2015 to Q4 2025

Type / Class
Equity / Common Shares, no par value
Symbol
XBIT on Nasdaq
Shares outstanding
30,767,343
Price per share
$2.41
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
2,935,115
Total reported value
$7,807,395
% of total 13F portfolios
0%
Share change
-480,704
Value change
-$1,319,020
Number of holders
45
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of XBiotech Inc. - Common Shares, no par value (XBIT) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
SIMARD JOHN 20% $19,608,609 6,624,530 John Simard 31 Dec 2024
MCKENZIE W THORPE 9.7% $8,843,027 2,987,509 W. Thorpe McKenzie 31 Dec 2024

As of 30 Sep 2025, 45 institutional investors reported holding 2,935,115 shares of XBiotech Inc. - Common Shares, no par value (XBIT). This represents 9.5% of the company’s total 30,767,343 outstanding shares.

Institutional Holders of XBiotech Inc. - Common Shares, no par value (XBIT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 0 $0 -$8 $2.41 0
2025 Q3 2,935,115 $7,807,395 -$1,319,020 $2.66 45
2025 Q2 3,415,938 $10,142,998 -$3,226,972 $2.97 51
2025 Q1 4,477,932 $14,507,328 -$783,250 $3.24 54
2024 Q4 4,716,023 $18,630,449 -$1,607,591 $3.95 52
2024 Q3 4,851,370 $37,501,751 +$1,640,884 $7.73 49
2024 Q2 4,516,257 $23,225,887 +$2,717,548 $5.14 45
2024 Q1 3,994,379 $32,478,639 +$4,805,756 $8.13 45
2023 Q4 3,446,675 $13,792,459 +$206,630 $4.00 38
2023 Q3 3,395,054 $13,985,979 -$309,341 $4.12 37
2023 Q2 3,482,899 $20,688,616 +$5,850,538 $5.94 38
2023 Q1 2,494,753 $8,604,457 -$920,924 $3.45 35
2022 Q4 2,756,801 $9,674,374 -$1,050,261 $3.51 38
2022 Q3 3,058,800 $11,071,334 -$1,597,992 $3.62 42
2022 Q2 3,361,179 $18,918,124 -$4,783,312 $5.63 50
2022 Q1 4,019,753 $34,733,851 -$1,812,345 $8.64 58
2021 Q4 4,192,680 $46,664,901 -$2,791,641 $11.13 56
2021 Q3 4,334,553 $56,131,719 +$4,054,236 $12.95 62
2021 Q2 4,022,892 $66,543,749 -$4,616,131 $16.56 55
2021 Q1 4,312,643 $73,919,400 +$5,963,093 $17.17 64
2020 Q4 3,983,078 $62,349,705 +$385,249 $15.65 64
2020 Q3 3,945,423 $75,314,185 -$5,845,601 $19.09 68
2020 Q2 4,296,332 $58,903,257 -$336,681 $13.71 64
2020 Q1 4,386,857 $46,593,234 -$15,936,871 $10.62 60
2019 Q4 5,475,879 $102,209,050 +$15,797,762 $18.67 59
2019 Q3 4,913,694 $51,425,090 +$6,014,412 $10.46 47
2019 Q2 4,410,025 $33,425,690 +$13,189,450 $7.58 42
2019 Q1 2,545,942 $28,053,606 +$16,068,965 $11.02 37
2018 Q4 1,118,399 $5,682,279 -$1,902,904 $5.08 23
2018 Q3 1,526,110 $4,850,175 -$1,157,316 $3.18 21
2018 Q2 1,825,442 $8,178,246 -$6,187,980 $4.48 30
2018 Q1 3,165,674 $16,936,156 -$782,940 $5.35 42
2017 Q4 3,305,711 $13,020,785 -$2,280,443 $3.94 43
2017 Q3 3,883,211 $16,964,807 +$657,728 $4.37 45
2017 Q2 3,746,784 $17,604,623 -$1,872,632 $4.70 45
2017 Q1 3,597,093 $59,310,105 +$23,911,479 $16.48 47
2016 Q4 3,461,617 $35,024,345 +$1,307,528 $10.12 47
2016 Q3 3,292,636 $44,309,081 +$5,759,071 $13.46 47
2016 Q2 2,793,021 $58,425,421 +$31,398,671 $20.92 46
2016 Q1 1,321,183 $12,486,000 -$434,126 $9.45 32
2015 Q4 1,353,508 $14,703,326 +$5,646,861 $10.87 37
2015 Q3 763,606 $11,426,133 +$2,973,270 $14.94 30
2015 Q2 590,347 $10,616,741 +$10,616,744 $18.08 31